Cryptococcal Meningitis Treatment Granted QIDP Status

Share this content:
FDA logo.
FDA logo.

Viamet Pharmaceuticals announced that the Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to VT-1129 for the treatment of cryptococcal meningitis

In preclinical studies, VT-1129 exhibited potent activity against clinical Cryptococcus isolates, including highly fluconazole-resistant strains. In September 2014, the FDA had granted VT-1129 Orphan Drug designation.

VT-1129 is a potent and highly selective inhibitor of fungal CYP51 enzyme in Cryptococcus neoformans. CYP51, a metalloenzyme essential for fungal proliferation and survival, is the target of several marketed antifungal therapies.

For more information visit

You must be a registered member of Infectious Disease Advisor to post a comment.

Sign Up for Free e-newsletters